Temperature-sensitive liposomal formulation
AssigneeDuke University
InventorDavid Needham
Life of this patent
Estimating the term…
Abstract
A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the lipid bilayer, compared to that which would occur in the absence of the surface active agent. The surface active agent is present in the lipid bilayer membrane so as to not destabilize the membrane in the gel phase.
Claims68
A liposome, comprising a gel-phase lipid bilayer membrane having a phase transition temperature, and an active agent,
- wherein the gel-phase lipid bilayer membrane comprises:
- (a) one or more phospholipids selected from the group consisting of phosphatidyl cholines, phosphatidyl glycerols, phosphatidyl inositols, and phosphatidyl ethanolamines, wherein the one or more phospholipids have two acyl groups;
- and
- (b) one or more lysolipids selected from the group consisting of monoacylphosphatidyl cholines, monoacylphosphatidylglycerols, monoacylphosphatidylinositols, and monoacylphosphatidylethanolamines, wherein the one or more lysolipids have one acyl group;
- and
- wherein the active agent is selected from the group consisting of a pharmacologically active agent or a diagnostic agent;
- and
- wherein the phase transition temperature is 39 to 45° C., and,
- wherein the amount of the one or more lysolipids in the gel-phase lipid bilayer membrane is sufficient to increase a first percentage of active agent released from the liposome at the phase transition temperature, compared to a second percentage of active agent released in the absence of the one or more lysolipids.
A method of administering an active agent to a preselected target site in a subject's body, comprising:
- (a) administering a liposome containing the active agent, wherein the liposome comprises a gel-phase lipid bilayer membrane having a phase transition temperature, and an active agent,
- wherein the gel-phase lipid bilayer membrane comprises:
- (i) one or more phospholipids selected from the group consisting of phosphatidyl cholines, phosphatidyl glycerols, phosphatidyl inositols, and phosphatidyl ethanolamines, wherein the phospholipids have two acyl groups;
- and
- (ii) one or more lysolipids selected from the group consisting of monoacylphosphatidylcholines, monoacylphosphatidylglycerols, monoacylphosphatidylinositols, and monoacylphosphatidylethanolamines, wherein the one or more lysolipids have one acyl group;
- and
- wherein the active agent is selected from the group consisting of a pharmacologically active agent or a diagnostic agent;
- and
- (b) heating the subject's preselected target site to a temperature about 39° C. to 45° C. to release the active agent from the liposome at the target site;
- wherein the amount of the one or more lysolipids in the lipid bilayer membrane is sufficient to increase a first percentage of active agent released from the liposome at the phase transition temperature, compared to a second percentage of active agent released in the absence of the one or more lysolipids.
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier, and a liposome having a gel-phase lipid bilayer membrane having a phase transition temperature, and an active agent,
- wherein the gel-phase lipid bilayer membrane comprises:
- (a) one or more phospholipids selected from the group consisting of phosphatidyl cholines, phosphatidyl glycerols, phosphatidyl inositols, and phosphatidyl ethanolamines, wherein the one or more phospholipids have two acyl groups;
- and
- (b) one or more lysolipids selected from the group consisting of monoacylphosphatidylcholines, monoacylphosphatidylglycerols monoacylphosphatidylinositols and monacylphosphatidylethanolamines, wherein the one or more lysolipids have one acyl group;
- and
- wherein the active agent is selected from the group consisting of a pharmacologically active agent or a diagnostic agent;
- and
- wherein the phase transition temperature is 39 to 45° C.;
- and
- wherein the amount of the one or lysolipids in the gel-phase lipid bilayer membrane is sufficient to increase a first percentage of active agent released from the liposome at the phase transition temperature, compared to a second percentage of active agent released in the absence of one or more lysolipids.
Dependencies are inferred from the claim text.